Market Overview

Keryx Biopharmaceuticals Receives FDA Orphan Approval For Treatment of Neuroblastoma


Keryx Biopharmaceuticals (Nasdaq: KERX) receives FDA approval for treatment of Neuroblastoma.

Not FDA Approved for Orphan Indication

Keryx Biopharmaceuticals is up close to 10% this morning.

See Some of the Top Moving Indexes Here.

Posted-In: News FDA Markets Movers


Related Articles (KERX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters